UNSPSC 51431702: Benazeprilat

This classification denotes an ace inhibitor with the molecular formula C22H24N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JRM708L703, chemically known as 1h-1-benzazepine-1-acetic acid, 3-(((1s)-1-carboxy-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (3s)- but generally known as benazeprilat, which bears US NIH Compound Identifier 5463984. European Medicines Agency schedules Benazeprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05701MIG.

UNSPSC 51431702 Benazeprilat, a Commodity code, encompasses injectable cardiovascular medications and related products supplied to state and local emergency medical services, public health agencies, and cooperative purchasing consortia. State and local governments procure benazeprilat and similarly classified intravenous medications as part of Advanced Life Support formularies for fire rescue operations, hospital emergency departments, and regional EMS systems. The issuing bodies span municipal fire departments, state health agencies, and multi-state cooperative purchasing alliances. Recent solicitations show city purchasing departments managing direct procurements for emergency medications alongside state-level health commissions evaluating pharmacy benefit program restructuring and multi-state cooperatives consolidating pharmaceutical supply agreements across member jurisdictions.

The code sees activity across Florida, Texas, and Minnesota in the most recent opportunities. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB 26P00188, due April 8, 2026) for Tampa Fire Rescue, specifying 370 units of Labetalol HCI 100mg vials alongside epinephrine, adenosine, and diltiazem, with an estimated contract value of $40,000.00 and a one-year term plus two optional one-year renewals. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at restructuring the state's pharmacy benefit procurement model. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with contract effectiveness set for July 1, 2026. Tampa's solicitation carries a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount not to exceed $10,000.